Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes

Bone

Volumn 56, Issue 2, 2013, Pages 355-362

  Ardawi, Mohammed Salleh M ^a   Akhbar, Daad H ^a   AlShaikh, Abdulrahman ^a   Ahmed, Maimoona M ^a   Qari, Mohammed H ^a   Rouzi, Abdulrahim A ^a   Ali, Ahmed Y ^a   Abdulrafee, Adel A ^a   Saeda, Mamdouh Y ^a,b  

^a Aziz University   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Bone turnover markers; Diabetes; IGF 1; Postmenopausal women; Sclerostin

Indexed keywords

SCLEROSTIN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SPINE FRACTURE; SPINE RADIOGRAPHY; THORACIC SPINE;

BONE TURNOVER MARKERS; DIABETES; IGF-1; POSTMENOPAUSAL WOMEN; SCLEROSTIN;

AGED; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC MARKERS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; POSTMENOPAUSE; SPINAL FRACTURES;

EID: 84880957208     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.06.029     Document Type: Article

References (72)

1. Bonds D.E., Larson J.C., Schwartz A.V., Strotmeyer E.S., Robbins J., Rodriguez B.L., et al. Risk of fracture in women with type 2 diabetes: the women's health initiative observational study. J Clin Endocrinol Metab 2006, 91:3404-3410.
2. Vestergaard P. Discrepancies in bone and mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007, 18:427-444.
3. Epstein S., Leroith D. Diabetes and fragility fractures: a burgeoning epidemic?. Bone 2008, 43:3-6.
4. Giangregorio L.M., Leslie W.D., Lix L.M., Johansson H., Oden A., McCloskey E., et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012, 27:301-308.
5. Schwartz A.V., Vittinghoff E., Bauer D.C., Hillier T.A., Strotmeyer E.S., Ensrud K.E., et al. Study of osteoporotic fractures (SOC) research group; osteoporotic fractures in men (MrOS) research group; health, aging and body composition (Health ABC) research group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011, 305:2184-2192.
6. Ip W., Chiang Y.-T.A., Jin T. The involvement of the wnt signaling pathway and TCF7L2 in diabetes mellitus: the current understanding, dispute, and perspective. Cell & Bioscience 2012, 2:28.
7. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/β-catenin in mesencymal progenitor's controls osteoblast and chondrocyte differentiation during vertebrae skeletogenesis. Dev Cell 2005, 8:739-750.
8. Jian H., Shen X., Liu I., Semenov M., He X., Wang X.F. Smad3-dependent nuclear translocation of β-catenin is required for TGF-β1 induced proliferation of bone marrow- derived adult human mesenchymal stem cells. Genes Dev 2006, 20:666-674.
9. Liu X., Li C., Liu K., Cui C., Zhang Y., Liu Y. The influence of fluoride on the expression of inhibitors of Wnt/β-catenin signaling pathway in rat skin fibroblast cells. Biol Trace Elem Res 2012, 148:117-121.
10. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280:19883-19887.
11. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
12. Balemans W., Ebeling M., Patel N., van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
13. Li X., Omnisky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24(4):578-588.
14. Ominsky M.S., Vlasseros F., Jolette J., Smith S.Y., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25(5):948-959.
15. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26(1):19-26.
16. Welters H.J., Kulkarni R.N. Wnt signaling: relevance to β-cell biology and diabetes. Trends Endocrinol Metab 2008, 19:349-355.
17. Kanazawa A., Tsukada S., Sekine A., Tsunoda T., Takahashi A., Kashiwagi A., et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet 2004, 75:832-843.
18. van Lierop A.H., Hamdy N.A., van der Meer R.W., Jonker J.T., Lamb H.J., Rijzewijk L.J., et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol 2012, 166:711-716.
19. Gennari L., Merlotti D., Valenti R., Ceccarelli E., Ruvio M., Pietrinin M.G., et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012, 97:1737-1744.
20. Kasukawa Y., Miyakoshi N., Mohan S. The anabolic effects of GH/IGF system on bone. Curr Pharm Des 2005, 10:2577-2592.
21. Niu T., Rpse C.J. The insulin-like growth factor-1 gene and osteoporosis: a critical appraisal. Gene 2005, 361:38-56.
22. Garnero P., Sornay-Rendu E., Delmas P.D. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 2000, 355:898-899.
23. Sugimoto T., Nishiyama K., Kuribayashi F., Chihara K. Serum levels of insulin-like growth factor (IGF) 1, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 1997, 12:1272-1279.
24. Yamaguchi T., Kanatani M., Yamauchi M., Kaji H., Sugishita T., Baylink D.J., et al. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4 and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int 2006, 78:18-24.
25. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Serum insulin-like growth factor-1 is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2007, 18:1675-1681.
26. Kanazawa I., Yamaguchi T., Sugimoto T. Serum insulin-like growth factor-1 is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011, 22:1191-1198.
27. Pasco J.A., Henry M.J., Korn S., Nicholson G.C., Kotowicz M.A. Morphometric vertebral fractures of the lower thoracic and lumbar spine, physical function and quality of life in men. Osteoporos Int 2009, 20:787-792.
28. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
29. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000, 11:556-561.
30. Delmas P.D., Genant H.K., Crans G.G., Stock J.L., Wong M., Siris E., et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003, 33:522-532.
31. von der Recke P., Hansen M.A., Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999, 106:273-278.
32. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28:S37-S42.
33. Wilson P.W., Paffenbarger R.S., Morris J.N., Havlik R.J. Assessment methods for physical activity and physical fitness in population studies: report of a NHLBI workshop. Am Heart J 1986, 111:1177-1192.
34. Ardawi M.-S.M., Al-Kadi H.A., Rouzi A.A., Qari M.H. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011, 26(12):2812-2822.
35. Genant H.K., Jergas M., Palermo L., Nevitt M., Valentin R.S., Black D., et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 2006, 11:984-996.
36. Kerkeni S., Kolta S., Fechtenbaum J., Roux C. Spinal deformity index (SDI) is a good predictor of incident vertebral fractures. Osteoporos Int 2009, 20:1547-1552.
37. Modder U.I.L., Clowes J.A., Hoey K., Peterson J.M., McCready L., Oursler M.J., et al. Regulation of circulating sclerostin levels by sex steroids in women and men. J Bone Miner Res 2011, 26(1):27-34.
38. Ardawi M.-S.M., Maimani A.A., Bahksh T.A., Rouzi A.A., Qari M.H., Radaddi R.M. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study. Bone 2010, 47:804-814.
39. Schwartz A.V., Sellmeyer D.E., Ensrud K.E., Cauley J.A., Tabor H.K., Schreiner P.J., et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001, 86:32-38.
40. Mobini M., Kashi Z., Bahar A., Taslimi F., Forghanizadeh J., Abdi R. Osteoporosis and osteoporotic fractures in postmenopausal women with type 2 diabetic compared with non-diabetic cases. Iran J Diab Obes 2012, 4:68-73.
41. Kilpadi K.L., ElDabaje R., Schmitz J.E., Ehler B., Thames T.A., Joshi A.P., et al. Type 2 diabetes is associated with vertebral fractures in a sample of clinic- and hospital-based Latinos. J Immigr Minor Health 2013, 10.1007/s10903-013-9833-5.
42. Chung D.J., Choi H.J., Chung Y.S., Lim S.K., Yang S.O., Shin C.S. The prevalence and risk factors of vertebral fractures in Korean patients with type 2 diabetes. J Bone Miner Metab 2013, 31:161-168.
43. Yamamoto M., Yamaguchi T., Yamauchi M., Kaji H., Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009, 24:702-709.
44. Yamamoto M., Yamaguchi T., Yamauchi M., Yano S., Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008, 93(3):1013-1019.
45. Clark P., Cons-Molina F., Deleze M., Ragi S., Haddock L., Zanchetta J.R., et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American vertebral osteoporosis study (LAVOS). Osteoporos Int 2009, 20:275-282.
46. Di Somma C., Rubino M., Faggiano A., Vuolo L., Contaldi P., Tafuto N., et al. Spinal deformity index in patients with type 2 diabetes. Endocrine 2013, 43:651-658.
47. Garcia-Martin A., Rozas-Moreno P., Reyes-Garcia R., Morales-Santana S., Garcia- Fontana B., Garcia-Salcedo J.A., et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97:234-241.
48. van Lierop A.H., Hamdy N.A., van der Meer R.W., Jonker J.T., Lamb H.J., Rijzewijk L.J., et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in menwith type 2 diabetes mellitus. Eur J Endocrinol 2012, 166:711-716.
49. Gaudio A., Privitera F., Battaglia K., Torrisi V., Sidoti M.H., Pulvirenti I., et al. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97(10):3744-3750.
50. Yamamoto M., Yamaguchi T., Nawata K., Yamauchi M., Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:1277-1284.
51. van Lierop A.H., Hamdy N.A., Hamersma H., van Bezooijen R.L., Power J., Loveridge N., et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011, 26:2804-2811.
52. Lin C., Jiang X., Dai Z., Gou X., Weng T., Wang J., et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res 2009, 24:1651-1661.
53. Gaudio A., Pennisi P., Bratengeier C., Torrisi V., Lindner B., Mangiafico R.A., et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010, 95:2248-2253.
54. Drake M.T., Srinivasan B., Modder U.I., Peterson J.M., McCready L.K., Riggs B.L., et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010, 95:5056-5062.
55. Yu E.W., Kumbhani R., Siwila-Sackman E., Leder B.Z. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab 2011, 96:1848-1851.
56. Modder U.I., Hoey K.A., Amin S., McCready L.K., Achenbach S.J., Riggs B.L., et al. Relation of age, gender and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011, 26:373-379.
57. Ueland T. Bone metabolism is relation to alterations in systemic growth hormone. Growth Horm IGF Res 2004, 14:404-417.
58. McCarthy T.L., Centrella M., Canalis E. Insulin-like growth factor (IGF) and bone. Connect Tissue Res 1989, 20:277-282.
59. Mohan S. Insulin-like growth factor binding proteins in bone cell regulation. Growth Regul 1993, 3:67-70.
60. Zhang M., Xuan S., Bouxsein M.L., von Stechow D., Akeno N., Faugere M.C., et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals and essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002, 277:44005-44012.
61. Saito M., Fujii K., Mori Y., Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006, 17:1514-1523.
62. Cappola A.R., Bandeen-roche K., Wand G.S., Volpato S., Fried L.P. Association of IGF-1 levels with muscle strength and mobility in older women. J Clin Endocrinol Metab 2001, 86:4139-4146.
63. Fechtenbaum J., Cropet C., Kolta S., Horlait S., Orcel P., Roux C. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 2005, 16:2175-2179.
64. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, Therapy2001 Osteoporosis prevention, diagnosis, and therapy, March 7-29: highlights of the conference. South Med J 2000, 94:569-573.
65. Gerdhem P., Isaksson A., Akesson K., Obrant K.J. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 2005, 16:1506-1512.
66. Verhaeghe J., van Herck E., Visser W.J., Suiker A.M., Thomasset M., Einhorn T.A., et al. Bone and mineral metabolism in BB rats with long-term diabetes. Decreased bone turnover and osteoporosis. Diabetes 1990, 39:477-482.
67. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1998, 318:1315-1321.
68. Wang X., Shen X., Li X., Agrawal C.M. Age-related changes in the collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2002, 79:160-168.
69. Saito M., Fujii K., Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2006, 79:160-168.
70. Schwartz A.V. Diabetes mellitus: does it affect bone?. Calcif Tissue Int 2003, 73:515-519.
71. Gregg E.W., Beckle G., Williams D.F., Leveille S.G., Langlois J.A., Engelgau M.M., et al. Diabetes and physical disability among older U.S. adults. Diabetes Care 2000, 23:1272-1277.
72. McNulty M., Singh R.J., Li X., Bergstralh E.J., Kumar R. Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 2011, 96:E1159-E1162.